BAYER AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.25 EUR | +0.65% |
|
-4.81% | -21.94% |
| 06:20am | Study: US companies outpace Europe and Asia in research spending | DP |
| Apr. 17 | Stifel Cuts Bayer PT, Keeps Hold Rating | MT |
| Sales 2024 * | 47.23B 50.43B | Sales 2025 * | 48.12B 51.38B | Capitalization | 25.79B 27.54B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.36B 2.51B | Net income 2025 * | 3.21B 3.42B | EV / Sales 2024 * | 1.24 x |
| Net Debt 2024 * | 32.81B 35.03B | Net Debt 2025 * | 29.7B 31.72B | EV / Sales 2025 * | 1.15 x |
| P/E ratio 2024 * |
11.3
x | P/E ratio 2025 * |
7.97
x | Employees | 96,931 |
| Yield 2024 * |
1.3% | Yield 2025 * |
1.43% | Free-Float | 99.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bayer AG
More press releases
More news
| 1 day | +0.65% | ||
| 1 week | -4.81% | ||
| Current month | -7.67% | ||
| 1 month | +0.06% | ||
| 3 months | -20.95% | ||
| 6 months | -39.24% | ||
| Current year | -21.94% |
1 week
25.92
27.83
1 month
25.7128.94
Current year
24.9636.09
1 year
24.9661.57
3 years
24.9667.99
5 years
24.9678.34
10 years
24.96146.45
| Managers | Title | Age | Since |
|---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 57 | 23-03-31 |
| Director of Finance/CFO | 54 | 18-04-25 | |
Bijoy Sagar
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Colleen Goggins
BRD | Director/Board Member | 68 | 17-03-31 |
| Director/Board Member | 68 | 17-03-31 | |
Alberto Weisser
BRD | Director/Board Member | 67 | 21-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.77% | 70 M€ | -.--% | - | |
| 5.71% | 2 M€ | +13.56% | - | |
| 4.28% | 962 M€ | -.--% | - | |
| 4.10% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 26.25 | +0.65% | 2,359,047 |
| 24-04-16 | 26.08 | -1.44% | 3,296,976 |
| 24-04-15 | 26.46 | -1.87% | 4,111,723 |
| 24-04-12 | 26.96 | -0.20% | 3,638,040 |
| 24-04-11 | 27.02 | -2.01% | 3,313,778 |
Delayed Quote Xetra, April 17, 2024 at 11:35 am EDT
More quotes
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows:
- agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.;
- pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.;
- OTC products and nutritional supplements (12.7%);
- other (0.5%).
Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).
Sector
Pharmaceuticals
Calendar
2024-04-26
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
26.25
EUR
Average target price
37.05
EUR
Spread / Average Target
+41.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.94% | 27.44B | |
| +28.79% | 676B | |
| +24.81% | 554B | |
| -7.64% | 349B | |
| +15.00% | 318B | |
| +5.99% | 291B | |
| +2.47% | 210B | |
| -0.02% | 204B | |
| -9.98% | 194B | |
| -11.71% | 144B |
- Stock Market
- Equities
- BAYN Stock
